We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Breath-Based Biomarkers Identified for Tuberculosis Diagnosis

By LabMedica International staff writers
Posted on 19 Dec 2022
Image: The R-Tube is designed for ease of use and this non-invasive handheld device is fully self-contained and disposable (Photo courtesy of Respiratory Research)
Image: The R-Tube is designed for ease of use and this non-invasive handheld device is fully self-contained and disposable (Photo courtesy of Respiratory Research)

Tuberculosis (TB) remains one of the top ten causes of death worldwide and is the leading cause of death from a single infectious agent. About a quarter of the world’s population is infected with Mycobacterium tuberculosis (Mtb), and thus at risk of developing TB.

Most conventional diagnostic tests rely on sputum samples, which can be difficult to obtain and have low diagnostic sensitivity in children, HIV-infected individuals and patients with extrapulmonary TB. Therefore, the ideal diagnostic would not rely on sputum samples, and can also detect non-pulmonary TB.

Medical Scientists at the University of Toulouse III-Paul Sabatier (Toulouse, France) and their numerous colleagues included in a study eight patients between 27 and 62 years old, diagnosed with pulmonary TB by direct Ziehl-Neelsen staining and culture of sputum; 21 patients with at least three sputum samples negative for Ziehl-Neelsen staining; children (aged 6–12) were separated into two groups based on the detection or not of mycobacteria; 15 adults (aged 18–61) who presented with community-acquired pneumonia and 15 healthy adult individuals. With the goal of developing a non-sputum-based TB diagnostic, the team examined whether pulmonary TB could be detected in exhaled breath condensate (EBC) samples.

The EBCs were collected using R-tubes (Respiratory Research, Inc, Austin, TX, USA). EBCs were lyophilized and adjusted to a volume of 250 µL of LPS-free water. EBCs were spotted using the Bio-Dot SF blotting apparatus (Bio-Rad, Hercules, CA, USA) and used for Dot-blot immunoassays. The scientists then performed monosaccharide analysis and quantification by capillary electrophoresis monitored by laser-induced fluorescence (CE-LIF). MALDI-TOF analyses were performed on an AB Sciex TOF/TOF 5800 mass spectrometer using the reflectron mode (Framingham, MA, USA).

The investigators reported that that the presence of M. tuberculosis-specific lipids, lipoarabinomannan lipoglycan, and proteins in EBCs can efficiently differentiate baseline TB patients from controls. They used EBCs to track the longitudinal effects of antibiotic treatment in pediatric TB patients. In addition, M. tuberculosis lipoarabinomannan and lipids were structurally distinct in EBCs compared to ex vivo cultured bacteria, revealing specific metabolic and biochemical states of M. tuberculosis in the human lung.

The authors concluded that sampling exhaled air is non-invasive and appears to be a powerful approach that overcomes the limitations in existing assays. An EBC-based approach therefore has potentially broad application for following other pulmonary infectious agents. The study was published on December 14, 2022 in the journal Nature Communications.

Related Links:
University of Toulouse III-Paul Sabatier
Respiratory Research
Bio-Rad
AB Sciex

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Alcohol Testing Device
Dräger Alcotest 7000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more